List of drugs that should be handled as hazardous*

List of drugs that should be handled as hazardous* Aldesleukin 4,5 10:00 Antineoplastic agents Alemtuzumab 1,3,4,5 10:00 Antineoplastic agents Alitretinoin 3,4,5 84:36 Miscellaneous skin and mucous membrane agents (Retinoid) Altretamine 1,2,3,4,5 Not in AHFS (Antineoplastic agent) Amsacrine 3,5 Not in AHFS (Antineoplastic agent) Anastrozole 1,5 10:00 Antineoplastic agents Arsenic trioxide 1,2,3,4,5 10:00 Antineoplastic agents Asparaginase 1,2,3,4,5 10:00 Antineoplastic agents Azacitidine 3,5 Not in AHFS (antineoplastic agent) Azathioprine 2,3,5 92:00 Unclassified therapeutic agents (immunosuppressant) Bacillus Calmette-Guerin 1,2,4 80:12 Vaccines Bexarotene 2,3,4,5 10:00 Antineoplastic agents Bicalutamide 1,5 10:00 Antineoplastic agents Bleomycin 1,2,3,4,5 10:00 Antineoplastic agents Busulfan 1,2,3,4,5 10:00 Antineoplastic agents Capecitabine 1,2,3,4,5 10:00 Antineoplastic agents Carboplatin 1,2,3,4,5 10:00 Antineoplastic agents Carmustine 1,2,3,4,5 10:00 Antineoplastic agents Cetrorelix acetate 5 92:00 Unclassified therapeutic agents (GnRH antagonist) Chlorambucil 1,2,3,4,5 10:00 Antineoplastic agents Chloramphenicol 1,5 8:12 Antibiotics Choriogonadotropin alfa 5 68:18 Gonadotropins Cidofovir 3,5 8:18 Antivirals Cisplatin 1,2,3,4,5 10:00 Antineoplastic agents Cladribine 1,2,3,4,5 10:00 Antineoplastic agents Colchicine 5 92:00 Unclassified therapeutic agents (mitotic inhibitor) Cyclophosphamide 1,2,3,4,5 10:00 Antineoplastic agents Cytarabine 1,2,3,4,5 10:00 Antineoplastic agents Cyclosporin 1 92:00 Immunosuppressive agents Dacarbazine 1,2,3,4,5 10:00 Antineoplastic agents Dactinomycin 1,2,3,4,5 10:00 Antineoplastic agents Daunorubicin HCl 1,2,3,4,5 10:00 Antineoplastic agents Denileukin 3,4,5 10:00 Antineoplastic agents Dienestrol 5 68:16.04 Estrogens Diethylstilbestrol 5 Not in AHFS (nonsteroidal synthetic estrogen) Dinoprostone 5 76:00 Oxytocics Docetaxel 1,2,3,4,5 10:00 Antineoplastic agents Doxorubicin 1,2,3,4,5 10:00 Antineoplastic agents Dutasteride 5 92:00 Unclassified therapeutic agents (5-alpha reductase inhibitor) Epirubicin 1,2,3,4,5 10:00 Antineoplastic agents Ergonovine/methylergonovine 5 76:00 Oxytocics Estradiol 1,5 68:16.04 Estrogens Estramustine phosphate sodium 1,2,3,4,5 10:00 Antineoplastic agents Estrogen-progestin combinations 5 68:12 Contraceptives Estrogens, conjugated 5 68:16.04 Estrogens Estrogens, esterified 5 68:16.04 Estrogens Estrone 5 68:16.04 Estrogens Estropipate 5 68:16.04 Estrogens Etoposide 1,2,3,4,5 10:00 Antineoplastic agents Exemestane 1,5 10:00 Antineoplastic agents Finasteride 1,3,5 92:00 Unclassified therapeutic Agents (5-alpha reductase inhibitor) Floxuridine 1,2,3,4,5 10:00 Antineoplastic agents (Fludarabine 1,2,3,4,5 10:00 Antineoplastic agents Fluorouracil 1,2,3,4,5 10:00 Antineoplastic agents Fluoxymesterone 5 68:08 Androgens Flutamide 1,2,5 10:00 Antineoplastic agents Fulvestrant 5 10:00 Antineoplastic agents Ganciclovir 1,2,3,4,5 8:18 Antiviral Ganirelix acetate 5 92:00 Unclassified therapeutic agents (GnRH antagonist) Gemcitabine 1,2,3,4,5 10:00 Antineoplastic agents Gemtuzumab ozogamicin 1,3,4,5 10:00 Antineoplastic agents Gonadotropin, chorionic 5 68:18 Gonadotropins Goserelin 1,2,5 10:00 Antineoplastic agents Hydroxyurea 1,2,3,4,5 10:00 Antineoplastic agents Ibritumomab tiuxetan 3 10:00 Antineoplastic agents Idarubicin 1,2,3,4,5 Not in AHFS (antineoplastic agent) Ifosfamide 1,2,3,4,5 10:00 Antineoplastic agents Imatinib mesylate 1,3,4,5 10:00 Antineoplastic agents Interferon alfa-2a 1,2,4,5 10:00 Antineoplastic agents Interferon alfa-2b 1,2,4,5 10:00 Antineoplastic agents Interferon alfa-n1 1,5 10:00 Antineoplastic agents Interferon alfa-n3 1,5 10:00 Antineoplastic agents Irinotecan HCl 1,2,3,4,5 10:00 Antineoplastic agents Leflunomide 3,5 92:00 Unclassified therapeutic agents (antineoplastic agent) Letrozole 1,5 10:00 Antineoplastic agents Leuprolide acetate 1,2,5 10:00 Antineoplastic agents Lomustine 1,2,3,4,5 10:00 Antineoplastic agents Mechlorethamine 1,2,3,4,5 10:00 Antineoplastic agents Megestrol 1,5 10:00 Antineoplastic agents Melphalan 1,2,3,4,5 10:00 Antineoplastic agents Menotropins 5 68:18 Gonadotropins Mercaptopurine 1,2,3,4,5 10:00 Antineoplastic agents Methotrexate 1,2,3,4,5 10:00 Antineoplastic agents Methyltestosterone 5 68:08 Androgens Mifepristone 5 76:00 Oxytocics Mitomycin 1,2,3,4,5 10:00 Antineoplastic agents Mitotane 1,4,5 10:00 Antineoplastic agents Mitoxantrone HCl 1,2,3,4,5 10:00 Antineoplastic agents Mycophenolate mofetil 1,3,5 92:00 Immunosuppressive agents Nafarelin 5 68:18 Gonadotropins Nilutamide 1,5 10:00 Antineoplastic agents Oxaliplatin 1,3,4,5 10:00 Antineoplastic agents Oxytocin 5 76:00 Oxytocics Paclitaxel 1,2,3,4,5 10:00 Antineoplastic agents Pegaspargase 1,2,3,4,5 10:00 Antineoplastic agents Pentamidine isethionate 1,2,3,5 8:40 Miscellaneous anti-infectives Pentostatin 1,2,3,4,5 10:00 Antineoplastic agents Perphosphamide 3,5 Not in AHFS (antineoplastic agent) Pipobroman 3,5 Not in AHFS (antineoplastic agent) Piritrexim isethionate 3,5 Not in AHFS (antineoplastic agent) Plicamycin 1,2,3,5 Not in AHFS (antineoplastic agent) Podoflilox 5 84:36 Miscellaneous skin and mucous membrane agents (mitotic inhibitor) Podophyllum resin 5 84:36 Miscellaneous skin and mucous membrane agents (mitotic inhibitor) Prednimustine 3,5 Not in AHFS (antineoplastic agent) Procarbazine 1,2,3,4,5 10:00 Antineoplastic agents Progesterone 5 68:32 Progestins Progestins 5 68:12 Contraceptives Raloxifene 5 68:16.12 Estrogen agonists-antagonists Raltitrexed 5 Not in AHFS (antineoplastic agent) Ribavirin 1,2,5 8:18 Antiviral Streptozocin 1,2,3,4,5 10:00 Antineoplastic agents Tacrolimus 1,5 92:00 Unclassified therapeutic agents (immunosuppressant) Tamoxifen 1,2,5 10:00 Antineoplastic agents Temozolomide 3,4,5 10:00 Antineoplastic agents Teniposide 1,2,3,4,5 10:00 Antineoplastic agents Testolactone 5 10:00 Antineoplastic agents Testosterone 5 68:08 Androgens Thalidomide 1,3,5 92:00 Unclassified therapeutic agents (immunomodulator) Thioguanine 1,2,3,4,5 10:00 Antineoplastic agents Thiotepa 1,2,3,4,5 10:00 Antineoplastic agents Topotecan 1,2,3,4,5 10:00 Antineoplastic agents Toremifene citrate 1,5 10:00 Antineoplastic agents Tositumomab 3,5 Not in AHFS (antineoplastic agent) Tretinoin 1,2,3,5 84:16 Cell stimulants and proliferants (retinoid) Trifluridine 1,2,5 52:04.06 antivirals Trimetrexate glucuronate 5 8:40 Miscellaneous anti-infectives (folate antagonist) Triptorelin 5 10:00 Antineoplastic agents Uracil mustard 3,5 Not in AHFS (antineoplastic agent) Valganciclovir 1,3,5 8:18 Antiviral Valrubicin 1,2,3,5 10:00 Antineoplastic agents Vidarabine 1,2,5 52:04.06 Antivirals Vinblastine sulfate 1,2,3,4,5 10:00 Antineoplastic agents Vincristine sulfate 1,2,3,4,5 10:00 Antineoplastic agents Vindesine 1,5 Not in AHFS (antineoplastic agent) Vinorelbine tartrate 1,2,3,4,5 10:00 Antineoplastic agents Zidovudine 1,2,5 8:18:08 Antiretroviral agents *These lists of hazardous drugs were used with the permission of the institutions that provided them and were adapted for use by NIOSH. The sample lists are intended to guide health care providers in diverse practice settings and should not be construed as complete representations of all of the hazardous drugs used at the referenced institutions. Some drugs defined as hazardous may not pose a significant risk of direct occupational exposure because of their dosage formulation (for example, intact medications such as coated tablets or capsules that are administered to patients without modifying the formulation). However, they may pose a risk if solid drug formulations are altered outside a ventilated cabinet (for example, if tablets are crushed or dissolved, or if capsules are pierced or opened). 1The NIH Clinical Center, Bethesda, MD (Revised 8/2002). The NIH Health Clinical Center Hazardous Drug (HD) List is part of the NIH Clinical Center’s hazard communication program. It was developed in compliance with the OSHA hazard communication standard [29 CFR 1910.1200] as it applies to hazardous drugs used in the workplace. The list is continually revised and represents the diversity of medical practice at the NIH Clinical Center; however, its content does not reflect an exhaustive review of all FDA-approved medications that may be considered hazardous, and it is not intended for use outside the NIH. 2The Johns Hopkins Hospital, Baltimore, MD (Revised 9/2002). 3The Northside Hospital, Atlanta, GA (Revised 8/2002). 4The University of Michigan Hospitals and Health Centers, Ann Arbor, MI (Revised 2/2003). 5This sample listing of hazardous drugs was compiled by the Pharmaceutical Research and Manufacturers of America (PhRMA) using information from the AHFS DI monographs published by ASHP in selected AHFS Pharmacologic-Therapeutic Classification categories [ASHP/AHFS DI 2003] and applying the definition for hazardous drugs. The list also includes drugs from other sources that satisfy the definition for hazardous drugs [PDR 2004; Sweetman 2002; Shepard 2001; Schardein 2000; REPROTOX 2003]. Newly approved drugs that have structures or toxicological profiles that mimic the drugs on this list should also be included. This list was revised in June 2004.

Source: http://dev.wfhealthcare.org/Wheaton/Employment/agency_staff/mke/documents/HazardousMeds.pdf